Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Only incidence and prevalence rates attributable to keratinocyte cancer, DALYs attributable to BCC would increase by 2050. (HealthDay News) — Older adults have a substantial and increasing ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

The mean monthly launch price increased from $10,954 to $27,891. The prices charged at the US launch of targeted cancer therapies have increased well above the rate of inflation every year since ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes. (HealthDay News) — For adults with diabetes and obesity, glucagon ...

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.